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SIGNIFICANCE
Lichen planus is a skin disease that may affect many diffe-
rent cutaneous or mucous parts of the body in individuals at 
all ages. Little is known of its incidence and long-term prog-
nosis. This study analysed the incidence of lichen planus 
in women and the mortality of lichen planus patients, based 
on nationwide Finnish registry data. The incidence was 28 
per 100,000 woman-years. The mortality of women with 
lichen planus was slightly increased because of excesses 
in mortality from several specific disease categories. These 
results confirm the importance of long-term and multidisci-
plinary follow-up of patients with lichen planus.
The incidence pattern of lichen planus (LP) and LP- 
related mortality are unknown. The aim of this study 
was to assess these factors, based on Finnish nation-
wide registry data including 13,378 women with LP 
diag nosed during 1969 to 2012. The incidence rate for 
LP in 2003 to 2012 was 28 per 100,000 woman-years 
age-adjusted to the European Standard Population. 
Mortality was assessed using the standardized morta-
lity ratio (SMR) with national mortality rates as the re-
ference. All-cause mortality was increased (SMR 1.07, 
95% confidence interval (95% CI) 1.02–1.11), with 
excess mortality from Hodgkin lymphoma (SMR 6.73, 
95% CI 1.83–17.2), non-Hodgkin lymphoma (SMR 
1.68, 95% CI 1.11–2.44), cancer of the oral cav ity 
(SMR 10.5, 95% CI 5.99–17.0), cancer of the tongue 
(SMR 7.25, 95% CI 3.13–14.3), infections (SMR 1.78, 
95% CI 1.14–2.64), respiratory diseases (SMR 1.31, 
95% CI 1.07–1.57), and diseases of the digestive sys-
tem (SMR 1.39, 95% CI 1.09–1.75). In conclusion, LP 
is a common disease and patients seem to have an im-
paired long-term prognosis.
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Lichen planus (LP) is a multifaceted disease of the skin and mucous membranes; it presents as many 
different subtypes and manifests in different parts of 
the body.
The most frequently affected site is the mucosa of the 
oral cavity (1, 2), and the second most common site is 
the skin (3). Oral LP affects women more often than men 
(4), whereas cutaneous LP shows no sex predilection (3). 
Infrequently affected sites of LP are the vulva, the vagina, 
the pharynx, the larynx, and the oesophagus. Despite the 
heterogeneity of the phenotypes of LP, all are caused by 
inflammation of the skin or mucous membranes. The 
aetiology of the inflammation, however, is unknown.
The exact incidence of LP and its different subtypes is 
unknown due to the care of patients with LP spreading 
across different medical specialties, in both primary and 
specialized healthcare. The crude incidence rate of LP in 
primary care in the UK between 1994 and 2003 was 38 
per 100,000 woman-years (5). Cutaneous LP is typically 
diagnosed in women in their 40s or 50s, and oral LP 10 
years later (2, 3). 
Treatment of LP is usually topical, with corticosteroid 
preparations as the gold standard (6). The erosive subtype 
may respond poorly to topical treatment, and systemic 
immunomodulatory agents are sometimes needed.
In the long run, cutaneous LP self-limits but often later 
recurs, and the mucosal variant is inevitably chronic 
(1–3). The quality of life of patients with LP is impaired 
(7). Long-term complications of erosive LP are scarring 
and malignant transformation (8, 9). Even though LP is 
known to cause significant morbidity, little is known of 
its effects on mortality.
The aim of this study was to assess the incidence of 
LP in women using nationwide hospital-based data from 
Finland. In addition, this study assessed the all-cause and 
cause-specific mortality of women diagnosed with LP.
MATERIALS AND METHODS
Data for this longitudinal descriptive study of all women in Finland 
were gathered from nationwide registries. All Finnish citizens are 
given a unique personal identification code at birth or immigration, 
which allows for identifying them in different registries.
Women diagnosed with LP between 1969 and 2012 were retriev-
ed from the Hospital Discharge Registry (HDR) maintained by 
the Finnish Institute for Health and Welfare. This registry gathers 
both primary and secondary inpatient diagnoses starting from 
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1969, and all outpatient diagnoses from public hospitals from the 
beginning of 1998. Diagnoses within the HDR are recorded with 
the International Statistical Classification of Diseases and Related 
Health Problems (ICD) system: ICD-8 in 1969 to 1986, ICD-9 
in 1987 to 1995, and ICD-10 since 1996. Before the 1980s, the 
reporting of all diagnosis codes to the HDR required manual input, 
and from the 1980s onwards, an automated electronic system has 
been adopted.
Data for all women with LP as a primary or secondary diagnosis 
code within the HDR between 1969 and 2012 were gathered for 
this study. The utilized ICD codes are specified in Table SI1.
Causes of death were retrieved from the Cause-of-Death Reg-
istry of Statistics Finland, where such data are collected since 
1936. After death, the physician in charge usually issues the death 
certificate with the ICD code for the underlying cause of death. If 
an autopsy is required, the forensic pathologist defines the cause 
of death based on the findings of the autopsy. For comparing 
causes of death over the years, Statistics Finland has produced a 
54-category short list for time series from 1971, which was used 
in this study (10). 
For deaths of cancer patients, data from the Finnish Cancer Reg-
istry (FCR) were used. All cancer diagnoses have been reported 
to this registry since 1953. In addition, the registry is informed of 
deaths from Statistics Finland. In the case of a death of a cancer 
patient, the FCR reassesses whether the death was specifically 
due to the cancer. 
The accuracy and completeness of data in the 3 aforementioned 
registries has been validated in several studies (11–13).
The dates for deaths and emigration were available from the 
national Population Register, kept by the Digital and Population 
Data Services Agency. Demographic data of the Finnish female 
population were taken from Statistics Finland.
The calculation of the incidence of LP was restricted to the last 
10 years of the study period, i.e. 2003 to 2012, to avoid inclusion 
of prevalent cases whose first diagnosis was before the HDR started 
to collect data. For mortality, all women diagnosed during 1969 to 
2012 were included. Follow-up for death began at the first diagno-
sis of LP or on January 1, 1971 (whichever was later). Follow-up 
ended in emigration, death, or on 31 December 2014, whichever 
came first. Women, who have both been diagnosed with LP and 
died between 1969 and 1971, should be excluded, but there were 
no such women in the study cohort.
The crude incidence rate of LP was calculated by dividing the 
number of new diagnoses by the size of the Finnish female popula-
tion each year. The incidence rates were calculated by 5-year age 
groups and were age-adjusted both to the European Standard 2013 
Population and to the World Standard Population. 
Standardized mortality ratios (SMR) for all-cause and cause-
specific deaths were calculated as ratios of the observed and the 
expected numbers of death. The observed deaths and person-years 
of follow-up were stratified by 5-year age groups, calendar periods, 
and follow-up periods (< 5 years, ≥ 5 years since the LP diagnosis). 
The expected numbers of deaths were calculated by multiplying 
the person-years of follow-up in each stratum with the respective 
mortality rate in the Finnish female population. These rates were 
obtained from Statistics Finland for non-cancer deaths, and from 
the FCR for cancer deaths. For the 95% confidence intervals (CI) 
a Poisson distribution of the observed deaths was assumed. 
Permission for this study was obtained from the Finnish Institute 
for Health and Welfare (THL/1440/5.05.00/2013). Permission for 
use of the data on the causes of death was given by Statistics Fin-
land (TK-53-1712-17). In Finland, no ethics committee approval 
is required for register-based studies.
RESULTS
The whole cohort of women with LP from 1969 to 2012 
consisted of 13,378 women (Table I), of whom 84% 
had been diagnosed in outpatient settings and 16% in 
inpatient settings. LP was most often the primary reason 
for the hospital visit for the women in the cohort: LP was 
a primary diagnosis code for 84% of women diagnosed 
in inpatient settings and for 96% of women diagnosed 
in outpatient settings. 
For incidence calculations between 2003 and 2012, 
7,761 women were included. Of these women, 98% 
were diagnosed in outpatient settings and 2% in inpa-
tient settings. LP was a primary diagnosis code in 95% 
of patients.
The crude and age-adjusted incidence rates (European 
Standard Population) were similar and remained stabile 
between 2003 and 2012, at 26–31 per 100,000 woman-
years (Fig. 1). The respective rate adjusted for age 
according to the World Standard Population fluctuated 
between 17 and 20 per 100,000 woman-years.
The age-specific incidence rate was low in girls and 
increased slowly through the reproductive years (Fig. 
2). The incidence was highest in women in the peri-
menopausal and postmenopausal age groups and reached 
its maximum (64 per 100,000 woman-years) in women 
aged 65 to 69 years. 
Table I. Number of patients with lichen planus by age at the beginning 






0–9 years    51 (0.4)     182 (0.1)
10–19 years  164 (1.2)     943 (0.7)
20–29 years  453 (3.4)   3,051 (2.1)
30–39 years  982 (7.3)   7,081 (5.0)
40–49 years 2,061 (15.4) 15,846 (11.1)
50–59 years 3,835 (28.7) 32,468 (22.7)
60–69 years 3,334 (24.9) 39,598 (27.7)
70–79 years 1,927 (14.4) 29,693 (20.8)
> 80 years  571 (4.3) 14,179 (9.9)
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Fig. 1. Crude and age-adjusted (European Standard Population 
(ESP) 2013) incidence rate of lichen planus in Finland 2003 to 
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For mortality calculations the whole cohort of 13,378 
patients with LP contributed altogether 143,040 person-
years and a mean of 10.7 years of follow-up (Table I). 
Most deaths in the cohort were due to the common causes 
of death of women in general; circulatory diseases, ma-
lignancies, dementia and Alzheimer’s disease (Table II).
The SMRs were invariably lower within the first 5 
years of follow-up than later on (Table SII1). This in-
dicates a healthy patient effect, and therefore, only the 
mortality figures of follow-up of more than 5 years are 
presented in Table II.
The all-cause mortality of women with LP was 
slightly increased (SMR 1.07, 95% CI 1.02–1.11) (Table 
II). The excess mortality arose from infections (SMR 
1.78, 95% CI 1.14–2.64), respiratory diseases (SMR 
1.31, 95% CI 1.07–1.57), bronchitis and emphysema 
(SMR 1.57, 95% CI 1.09–2.17), diseases of the diges-
tive system (SMR 1.39, 95% CI 1.09–1.75), and cancers 
(SMR 1.14, 95% CI 1.03–1.25) (Table II). There was 
excess mortality from cancers of the oral cavity (SMR 
10.5, 95% CI 5.99–17.0) and tongue (SMR 7.25, 95% 
CI 3.13–14.3), and from non-Hodgkin (SMR 1.68, 95% 
CI 1.11–2.44) and Hodgkin lymphoma (SMR 6.73, 95% 
CI 1.83–17.2).
DISCUSSION
In this nationwide study, the incidence of LP remained 
constant during 2003 to 2012: 28 per 100,000 woman-
years. LP diagnoses were rare in children, and the highest 
incidence was observed within postmenopausal age 
groups. The mortality of women with LP was somewhat 
higher than in the general female population due to excess 
mortality from respiratory diseases, lymphomas, cancers 
of the oral cavity and tongue, infections, and diseases of 
the digestive system.
A strength of this study is its data. Finnish registries 
have gathered data from the whole population for a long 
period of time. The registries are continuously evaluated 
for data accuracy and completeness (11–13). The cur-
rent study gained access to a large number of patients 
with LP and enabled data for the women to be merged 
between registries. 
However, registry data also entail limitations. The 
diagnosis codes used for LP do not specify the subtype 
or location of the disease. LP is a heterogeneous disease 
group with different phenotypes, and mortality may vary 
between them.
Furthermore, some of the diagnoses of LP may be 
incorrect. Diagnosing LP poses a challenge: many dif-
ferent diseases may mimic LP clinically. Moreover, the 
histological picture may be unspecific or highly variable. 
To overcome this problem, several diagnostic criteria 
for LP have been presented over the years. Some allow 
a clinical-only diagnosis, but recommend a biopsy in 
uncertain cases (14). Others require both typical clini-
Table II. Observed and expected numbers of deaths and standardized 
mortality ratios (SMR) with 95% confidence intervals (95% CI) 
for selected causes of death in women with lichen planus within a 
follow-up of more than 5 years
Cause of death Observed Expected SMR 95% CI
All causes 1,813 1,701 1.07 1.02–1.11
All diseases 1,742 1,636 1.06 1.02–1.11
  Infections   24 13 1.78 1.14–2.64
  Cancer 417 366 1.14 1.03–1.25
    Lip     1   0.2 6.85 0.17–38.2
    Tongue     8   1 7.25 3.13–14.3
    Oral cavity   16   1.53 10.5 5.99–17.0
    Pharynx     3   1 3.08 0.64–9.00
    Oesophagus     9   6 1.61 0.74–3.05
    Larynx     2   0.3 5.89 0.71–21.3
    Lung, trachea   50 41 1.22 0.90–1.60
    Breast   52 53 0.98 0.73–1.28
    Genitals   56 43 1.29 0.97–1.67
      Cervix uteri     2   4 0.53 0.06–1.89
      Corpus uteri   14 12 1.18 0.65–1.98
      Ovary   28 21 1.31 0.87–1.89
      Vulva     3   2 1.34 0.28–3.91
      Vagina     2   0.7 2.75 0.33–9.92
    Skin, non-melanoma     2   1 1.61 0.19–5.80
    Non-Hodgkin lymphoma   27 16 1.68 1.11–2.44
    Hodgkin lymphoma     4   0.6 6.73 1.83–17.2
  Endocrine, nutritional and 
metabolic diseases
  27 22 1.25 0.82–1.81
    Diabetes mellitus   22 18 1.22 0.76–1.83
  Dementia, Alzheimer’s disease 223 232 0.96 0.84–1.09
  Diseases of circulatory system 766 761 1.01 0.94–1.07
    Ischaemic heart diseases 429 403 1.07 0.97–1.16
    Other heart diseases   76   73 1.04 0.82–1.29
    Cerebrovascular diseases 185 198 0.94 0.81–1.07
  Diseases of respiratory system 105   80 1.31 1.07–1.57
    Bronchitis, emphysema   35   22 1.57 1.09–2.17
  Diseases of digestive system   73   52 1.39 1.09–1.75
  Diseases of genitourinary system   28   19 1.44 0.96–2.08
  Alcohol related diseases and 
accidental poisoning by alcohol
  11   19 0.59 0.30–1.06
Accidents and violence   68   62 1.09 0.85–1.38





























































Fig. 2. Age-specific incidence rates of lichen planus in Finland 2003 
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cal picture and confirmatory histology for diagnosis (6, 
15–17). Within registry data, the diagnostic procedure is 
not recorded. In the current cohort, there may be patients 
who have been clinically misdiagnosed or miscoded as 
having LP. Even so, we assume them to be few, because 
the LP diagnoses in the data have been made by special-
ists in secondary or tertiary care.
The study cohort includes patients hospitalized for LP 
from 1969 and patients treated in outpatient settings in 
hospitals from 1998. Therefore, the study cohort does 
not represent all women diagnosed in Finland with LP. 
The mildest cases of LP diagnosed and treated only in 
the primary healthcare are lacking in this study. The 
manual extraction and input of data into the HDR in the 
beginning of the study period may have been incomplete, 
leading to more patients missing. Therefore, the inci-
dence rates do not include all cases of LP, and the SMR 
results may not be generalizable to all patients with LP. 
The data available for this study do not include in-
formation on several factors known to affect mortality, 
such as smoking, alcohol consumption, body mass index, 
physical inactivity, diet, socioeconomic status, and parity. 
It is difficult to estimate whether the prevalence of those 
factors differs among patients with LP and the general 
population and therefore could cause bias in the SMRs. 
We do not know how patients in our cohort were 
treated. Systemic treatment, such as corticosteroids or 
methotrexate, could affect mortality. In psoriasis and 
psoriatic arthritis, methotrexate has been suggested to 
lower the risk of cardiovascular disease (18). In contrast, 
an increased risk of cardiovascular events was observed 
among users of oral corticosteroids in a population-based 
case-control study (19). Evidence in LP is lacking.
Previous research on the incidence of LP is scarce 
and done with small populations. In the UK, the crude 
incidence of any LP between 1994 and 2003 was 38 per 
100,000 woman-years, with data collected from a pool 
of patients observed by sentinel general practitioners 
(5). This is not comparable to our incidence rate because 
our cohort is based on patients diagnosed in specialized 
healthcare. The incidence of oral LP has varied greatly in 
3 studies: it was 14 per 100,000 woman-years calculated 
from health registers of Olmsted county, Minnesota in 
the USA, 188 per 100,000 in a screening programme in 
a Japanese city, and 250 per 100,000 among Indian villa-
gers (20–22). None of these rates are comparable to ours.
In previous literature, the mean age at the onset of 
symptoms or at diagnosis of LP has been 57–61 years 
for oral LP and 46 years for cutaneous LP (2, 3, 23). 
The current cohort includes patients with any LP and 
the mean age at diagnosis (57 years) is thus comparable 
to the previous estimates.
The lack of research on the mortality of patients with 
LP is pronounced. An older study compared the percent-
ages of causes of death among 50 patients with LP to 
several reference populations (24). Numbers of deaths 
in specific cause-of-death categories were small, and no 
systematic differences in mortality patterns of patients 
with LP and referents were found.
The cause for the elevated mortality in the LP cohort 
from diseases of many organ systems (infections, respi-
ratory diseases, digestive diseases) and from different 
cancers (cancer of the oral cavity and tongue, and lym-
phomas) remains ambiguous.
The increased mortality from infections could arise 
from the use of systemic immunosuppressing medica-
tions for treatment, whereas the increased mortality from 
respiratory diseases, mainly form bronchitis and em-
physema, most likely relates to patients with LP smoking 
more than the general population. The relationship of LP 
and smoking is controversial, but because mortality from 
lung cancer and respiratory diseases was increased in this 
study, we hypothesize that patients with LP smoke more 
than the general population.
Chronic inflammation may promote development of 
cancer, and several inflammatory diseases are known 
to increase the risk of cancer in organs where inflam-
mation is present (25). We demonstrated this in LP in a 
previous study: the risks of cancers of the mouth, larynx, 
oesophagus, and vulva were increased (9). Therefore, the 
increased mortality from cancers of the oral cavity and 
tongue in this study was expected. 
Some inflammatory diseases, such as rheumatoid 
arthritis and systemic lupus erythematosus, have been 
linked to increased risk of haematological malignancies 
due to systemic dysregulation of the immune system 
(25, 26). In this study, the mortality from non-Hodgkin 
and Hodgkin lymphomas was increased in women with 
LP. An increased risk of lymphomas has been observed 
in patients with psoriasis, another skin condition char-
acterized with local inflammation (27). In psoriasis, 
inflammation may span from a local to a systemic level 
(28), and therefore, it is tempting to speculate, that, in 
addition to local inflammation, LP also causes systemic 
alterations in the immune system. Another explanation 
for the link between LP and lymphomas could be shared 
predisposing factors.
Increased mortality from cancers of the oral cavity and 
tongue in the LP cohort could, in part, be explained by 
excess consumption of alcohol and smoking, well-known 
risk factors for these cancers. Alcohol consumption 
among the patients with LP is probably not high, since 
mortality from alcohol-related causes was reduced. How-
ever, as stated above, smoking may be more common 
among the women in this cohort.
This nationwide study of women diagnosed with LP in 
hospital settings shows a stabile incidence of LP, with a 
majority of diagnoses made among postmenopausal age 
groups. Excess mortality from diseases of some organ 
systems and cancers among these women is suggested. 
Therefore, the need for multidisciplinary treatment and 
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